Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta

Basit Öğe Kaydı
dc.contributor.authorHeidrich, Benjamin
dc.contributor.authorYurdaydın, Cihan
dc.contributor.authorKabacam, Gökhan
dc.contributor.authorRatsch, Boris A.
dc.contributor.authorZachou, Kalliopi
dc.contributor.authorBremer, Birgit
dc.contributor.authorDalekos, George N.
dc.contributor.authorYalçın, Kendal
dc.date.accessioned2024-04-24T15:59:24Z
dc.date.available2024-04-24T15:59:24Z
dc.date.issued2014
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractInterferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. However, the clinical and virological long-term outcome of HDV-infected patients treated with PEG-IFNa is unknown. We performed a retrospective-prospective follow-up of 77 patients treated for 48 weeks with either PEG-alfa-2a and adefovir (ADV) or either drug alone in the Hep-Net-International-Delta-Hepatitis-Intervention-Study 1 (HIDIT-1) trial. Long-term follow-up data were available for 58 out of 77 patients (75%) with a median time of follow-up of 4.5 (0.5-5.5) years and a median 3 visits per patient. Patients treated with ADV alone received retreatment with PEG-IFNa (48% versus 19%; P = 0.02) more often. Hepatitis B virus surface antigen (HBsAg) became negative in six PEG-IFNa-treated patients until the end of long-term follow-up (10%). Sixteen patients tested HDV RNA-negative 6 months after PEG-IFNa treatment who were entered in the long-term follow-up study. Out of these, nine individuals tested HDV RNA-positive at least once during further long-term follow-up, with seven patients being HDV RNA-positive at the most recent visit. Clinical endpoints (liver-related death, liver transplantation, hepatic decompensation, hepatocellular carcinoma) were observed in three PEG-IFNa-treated (8%) and three ADV-treated (14%) patients during posttreatment long-term follow-up with an overall annual event rate of 2.5% (4.9% in cirrhosis). Sequencing confirmed the reappearance of pretreatment virus strains in all cases. Conclusion: Late HDV RNA relapses may occur after PEG-IFNa therapy of hepatitis delta and thus the term sustained virological response should be avoided in HDV infection. The annual posttreatment rate of clinical events in hepatitis delta patients eligible for PEG-IFNa therapy is about 2.5% and 4.9% in patients with cirrhosis.en_US
dc.description.sponsorshipHep-Net Study House; German Liver Foundation; HepNet e.V.; Integrated Research and Treatment Center Transplantation (IFB-Tx Project 37) [01EO0802]; Hannover Medical School; German Centre for Infection Research (DZIF)en_US
dc.description.sponsorshipSupported by the Hep-Net Study House, the German Liver Foundation, the HepNet e.V. as well as in part by the Integrated Research and Treatment Center Transplantation (IFB-Tx Project 37; Reference No.: 01EO0802), Hannover Medical School, and the German Centre for Infection Research (DZIF)en_US
dc.identifier.citationHeidrich, B., Yurdaydın, C., Kabacam, G., Ratsch, B. A., Zachou, K., Bremer, B. ve diğerleri. (2014). Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta, 60(1), 87-97.
dc.identifier.doi10.1002/hep.27102
dc.identifier.endpage97en_US
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.issue1en_US
dc.identifier.pmid24585488
dc.identifier.scopus2-s2.0-84902091591
dc.identifier.scopusqualityQ1
dc.identifier.startpage87en_US
dc.identifier.urihttps://doi.org/10.1002/hep.27102
dc.identifier.urihttps://hdl.handle.net/11468/14040
dc.identifier.urihttps://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.27102
dc.identifier.volume60en_US
dc.identifier.wosWOS:000337969000014
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYalçın, Kendal
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofHepatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keyword]en_US
dc.titleLate HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis deltaen_US
dc.titleLate HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta.pdf
Boyut:
740.88 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu